| ANIXA BIOSCIENCES DL -,01 |
| USA |
| Gesundheit |
| US03528H1095 / A2N6ZF |
| CY71 (Frankfurt) / ANIX (NASDAQ) |
| FRA:CY71, ETR:CY71, CY71:GR, NASDAQ:ANIX |
| - |
| https://www.anixa.com/ |
|
Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines to address critical unmet needs in oncology, particularly for the treatment and prevention of cancer. Its primary programs include a chimeri..
>Volltext.. |
| 79 Mio. EUR |
| 66.15 Mio. EUR |
| - |
| -9.52 Mio. EUR |
| -8.93 Mio. EUR |
| -0.27 EUR |
| 0.17 Mio. EUR |
| 1.34 Mio. EUR |
| -5.96 Mio. EUR |
| 11.49 |
| - |
| 27.82% |
| - |
| - |
| - |
| - |
| ANIXA BIOSCIENCES, ANIXA BIOSCIENCE, ANIXA BIO |
| 05.04.26 |
|